Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results
Authors' conclusion
Treatment of pediatric GHD with lonapegsomatropin in the enliGHten trial provided robust growth outcomes and maintained a safety profile comparable to that of daily GH in a population with a broad range of pubertal statuses. </p>.
Study context
- Population
- Children with growth hormone deficiency (GHD) who previously participated in a phase 3 lonapegsomatropin trial (heiGHt or fliGHt)
- Outcome
- Height SDS
- Follow-up
- Year 4
Methodological detailsinternational, phase 3, 63 sites (15 countries)
- International
- Phase 3
- 63 sites (15 countries)
Main finding
As reported in the abstract
Lonapegsomatropin
−0.39
mean
Further findings
| Outcome | Values |
|---|---|
| Met or exceeded average parental height SDS at last visit, among participants completing treatment | Lonapegsomatropin 59.3% |
- Met or exceeded average parental height standard deviation score (SDS) at last visit, among participants completing treatment: 81 completed treatment for pediatric GHD
Weekly average IGF-1 SDS
- Mean weekly average IGF-1 remained within 0-2 SDS throughout the trial
Growth during puberty and dose
- Growth maintained throughout pubertal development; dose remained stable
Safety
Adverse events
- AEs mostly mild or moderate, consistent with prior reports of daily somatropin; no evidence of accelerated skeletal maturation or safety signals associated with anti-drug antibodies
Original publication
Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results. Horm Res Paediatr. Published 6 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →